Journal Home
Search for

Volume 62, Issue 1, Pages 45-53 (January 2010)


View previous. 20 of 60 View next.

Recurrent erythema multiforme: Clinical characteristics, etiologic associations, and treatment in a series of 48 patients at Mayo Clinic, 2000 to 2007

David A. Wetter, MD, Mark D.P. Davis, MDCorresponding Author Informationemail address

Accepted 10 June 2009. published online 10 August 2009.

Background

Recurrent erythema multiforme (EM) is a condition of substantial morbidity. Our efforts toward the etiologic attribution and treatment of recurrent EM have been less fruitful than those previously described.

Objective

We sought to further characterize clinical characteristics, etiologic associations, and treatment of recurrent EM.

Methods

We conducted a retrospective review of patients with recurrent EM seen between 2000 and 2007.

Results

Of 48 patients (mean age at disease onset, 36.4 years), 28 (58%) were female (mean duration of recurrent EM, 6 years). Thirty (63%) patients had oral involvement. Herpes simplex virus caused recurrent EM in 11 (23%) patients, and the cause remained unknown in 28 (58%). In all, 37 (77%) patients received systemic corticosteroids, 33 (69%) received continuous antiviral treatment, and 23 (48%) used immunosuppressive or anti-inflammatory agents. Sixteen of 33 patients receiving continuous antiviral treatment had either partial or complete disease suppression. Patients had varied responses to immunosuppressants, with mycophenolate mofetil providing partial or complete response in 6 of 8 patients. Features of recalcitrant cases included clinicians' inability to identify a specific cause, lack of improvement with continuous antiviral therapy, severe oral involvement, extensive corticosteroid therapy, and immunosuppressive therapy (two or more agents).

Limitation

This study is retrospective.

Conclusions

More than half of patients in this study did not have an identifiable cause for recurrent EM, and herpes simplex virus was found less frequently than reported in previous studies. Response to systemic treatments, including continuous antivirals and immunosuppressants, was varied and oftentimes suboptimal.

Department of Dermatology, Mayo Clinic, Rochester, Minnesota

Corresponding Author InformationReprint requests: Mark D. P. Davis, MD, Department of Dermatology, Mayo Clinic, 200 First St SW, Rochester, MN 55905.

 Funding sources: None.

 Conflicts of interest: None declared.

PII: S0190-9622(09)00778-6

doi:10.1016/j.jaad.2009.06.046


View previous. 20 of 60 View next.